Search Bar & Filters
Found 37 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.
Actively Recruiting
Researchers are evaluating the anti-tumor effects of amivantamab combined with pembrolizumab and carboplatin compared to pembrolizumab, 5-fluorouracil, and platinum therapy in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have not received prior treatment for their advanced cancer. HNSCC affects tissues in the mouth and throat, and this study focuses on treatment-naive participants in this setting. Participants are assigned to one of two groups one receives pembrolizumab, amivantamab, and carboplatin, while the other receives pembrolizumab, 5-fluorouracil given as a 4-day infusion, and either carboplatin or cisplatin. The study compares these treatment combinations to assess their effects on the cancer over a period of up to about 3 years and 7 months. During the study, participants undergo evaluations including imaging scans to measure tumor response using RECIST criteria, blood tests to monitor drug levels and antibodies, and quality of life questionnaires focused on head and neck symptoms and overall health. Researchers track overall survival, tumor response rates, progression-free survival, duration of response, side effects, and symptom changes. The study involves regular visits for treatment and monitoring throughout the treatment and follow-up period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma who have received multiple prior treatments. This Phase 2 study focuses on determining the recommended doses and assessing the treatment in different participant groups based on previous therapies received. The study is sponsored by Janssen Research & Development, LLC and aims to provide new treatment options for this condition. Participants are divided into five cohorts based on their treatment history, including exposure to T cell redirection therapies and prior medications. Talquetamab is administered subcutaneously at recommended Phase 2 doses, with dosing schedules including biweekly administration in some cohorts. All participants will transition to an open-label extension phase to continue receiving the study treatment, followed by a long-term extension phase upon sponsor approval. Throughout the study, participants will undergo regular assessments to measure treatment response, safety, and tolerability. These include evaluations of overall response rate, duration of response, progression-free survival, quality of life questionnaires, laboratory tests, and monitoring for adverse events. The study duration includes follow-up to approximately 2 years and 10 months. Talquetamab concentrations and antibody presence will also be monitored to understand treatment effects and immune response.
Actively Recruiting
Researchers are studying how well and safely elafibranor works compared to a placebo in adults with Primary Sclerosing Cholangitis PSC, a rare liver disease that causes inflammation and scarring of the bile ducts. PSC can lead to serious liver damage, potentially requiring a liver transplant or causing death. This phase III study involves about 350 participants with large duct PSC. Participants will be randomly assigned to take either elafibranor 120 mg once daily or a placebo tablet daily. The study includes a screening period, a treatment period expected to last about 5 years until enough health events occur, and a post-treatment safety follow-up lasting around four weeks. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Throughout the study, participants will have routine clinical assessments, lab tests, imaging evaluations, and patient-reported assessments to monitor disease progression, symptoms like pruritus and fatigue, quality of life, and safety. Researchers will measure event-free survival and monitor for adverse events and changes in vital signs and lab parameters. Participants may withdraw anytime, and the total study duration may extend over several years.
Actively Recruiting
This research aims to compare Axatilimab versus the best available therapy in children aged 2 to under 18 years with chronic graft-versus-host disease cGVHD who have already tried at least two previous systemic treatments. The study focuses on those with moderate to severe active cGVHD requiring ongoing immune suppression, including participants who have had prior stem cell transplants from various donor types and conditioning methods. Participants will be randomly assigned to receive either Axatilimab at a specific dose or a best available therapy selected by the investigator. The best available therapy may include drugs like cyclosporine, tacrolimus, extracorporeal photopheresis, mycophenolate mofetil, mTOR inhibitors, rituximab, imatinib, methotrexate, ibrutinib, or pentostatin, but excludes experimental agents not approved for any indication. Systemic corticosteroids are allowed if the dose is stable. Throughout the study, participants will be monitored for their response to treatment at 6 months and up to 5 years, including quality of life assessments and adverse events. Researchers will measure how well the disease responds, the pharmacokinetics of Axatilimab, reductions in corticosteroid use, and organ-specific effects. The total study duration includes treatment and long-term follow-up to evaluate safety and effectiveness outcomes.
Actively Recruiting
Researchers are studying CRB-701, a targeted chemotherapy known as an antibody drug conjugate, to see how well it works as a treatment for oropharyngeal throat, tonsil cancer in patients who have already had platinum-based chemotherapy or immunotherapy. The study also aims to learn about the safety of CRB-701 and how it affects participants quality of life, comparing it with standard care medicines commonly used for this cancer. Participants are randomly assigned to receive either CRB-701 at a dose of 3.6 mgkg intravenously every three weeks or one of the investigators choice therapies, which include capecitabine, cetuximab, or docetaxel. They will continue treatment until the cancer is no longer measurable or controlled. Treatment schedules vary by drug but generally follow cycles of 21 days, with imaging scans like CT or MRI every six weeks to assess cancer response. During the study, participants will visit the clinic every three weeks for infusions and undergo scans every six weeks to monitor their cancer. They will also complete questionnaires to assess their health status and quality of life. Researchers will track response rates, overall survival, progression-free survival, adverse events, and treatment modifications over approximately two to three years from randomization to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years old who have nonsegmental vitiligo. This phase 3 study aims to understand how well ruxolitinib cream works to improve skin depigmentation in this young population. The study compares two strengths of ruxolitinib cream against a placebo cream, with participants randomly assigned to one of the groups. Participants apply either 0.75% or 1.5% ruxolitinib cream, or a matching placebo cream, as a thin layer on the affected skin areas twice daily. The treatment lasts for 24 weeks, with the primary goal of measuring improvement in facial vitiligo area. The study also monitors other outcomes such as body vitiligo improvement, patient satisfaction, and possible side effects for up to 52 weeks. During the study, participants will be regularly assessed for changes in their vitiligo using standardized scoring indexes and questionnaires that measure the impact on quality of life. Blood samples will be taken at several points to study the drugs levels in the body. Safety is closely monitored, and participants are followed through a final safety visit. Overall participation can last up to around one year, including treatment and follow-up periods.
Actively Recruiting
Researchers are studying the safety, tolerability, and how the body processes maribavir in children and teenagers who have cytomegalovirus CMV infection after receiving a hematopoietic stem cell transplant HSCT or a solid organ transplant SOT. This phase 3 trial aims to find the best dose of maribavir using either a 200 mg tablet or a powder for oral suspension formulation. The study focuses on these young patients who have documented CMV infection and evaluates maribavirs antiviral activity along with its pharmacokinetics. Participants receive maribavir for up to 8 weeks with doses adjusted based on age and body weight. For ages 12 to less than 18 years, dosing ranges from 100 mg to 400 mg twice daily depending on weight. Those aged 6 to less than 12 years follow a similar dosing scheme, and children younger than 6 years may receive doses from 50 mg once or twice daily up to 400 mg twice daily. The medication is taken orally as tablets or powder for oral suspension during the treatment period. During the study, participants will have multiple blood tests to measure maribavir levels at various time points, and adverse events will be monitored up to 20 weeks. There is a 12-week follow-up period after treatment ends, during which participants will visit their doctor to assess continued viral control and safety. Researchers will also evaluate the clearance of CMV viremia, recurrence rates, and resistance development, along with participant feedback on medication palatability.
1-10 of 37
1